Summarized by Masters of Longevity from PR Newswire.
New ESMO data report durable first-line activity and manageable safety for a next-generation KRAS G12C inhibitor combined with PD-1 therapy, with or without chemotherapy.
Key Takeaways
- Olomorasib plus pembrolizumab showed durable responses with median PFS and DOR unreached.
- Olomorasib with chemoimmunotherapy achieved a 62% overall response rate and 14.5‑month DOR.
- Adverse events caused dose reductions and discontinuations, and no Grade 5 TRAEs occurred.
